372198-69-1

Basic information

• Product Name: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester
• Synonyms: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester;ethyl 6-broMoH-iMidazo[1,2-a]pyridine-3-carboxylate;6-Bromoimidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester;6-bromoImidazo[1,2-a]pyridine-3-Carbocylic acid ethyl ester;Midazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester
• CAS NO: 372198-69-1
• Molecular Formula: C₁₀H₉BrN₂O₂
• Molecular Weight: 269.09466
• Product Categories: Heterocycle-Pyridine series
• Mol File: 372198-69-1.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Density: 1.60
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.29±0.50(Predicted)
• CAS DataBase Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester(372198-69-1)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester(372198-69-1)

Safety Data

• Hazardous Substances Data: 372198-69-1(Hazardous Substances Data)

Usage

General Description

Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-bromo-, ethyl ester is a chemical compound with the molecular formula C11H9BrN2O2. It is a derivative of imidazopyridine and is commonly used in the pharmaceutical industry as a building block for the synthesis of various bioactive compounds. It has been studied for its potential use in the treatment of conditions such as cancer, inflammation, and neurological disorders. The ethyl ester form of the compound gives it enhanced solubility and stability, making it suitable for use in drug formulations.Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-bromo-, ethyl ester has also been investigated for its potential application in the field of material science, particularly in the development of organic semiconductors and optoelectronic devices.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 138240-34-3 (E)-N’-(5-bromopyridin-2-yl)-N,N-dimethylformamidine 
• 105-36-2 ethyl bromoacetate 
• 913287-11-3 2-chloro-3-oxopropanoate potassium salt 
• 33142-21-1 ethyl 2-chloro-3-oxopropanoate 
• 105-39-5 chloroacetic acid ethyl ester 
• 109-94-4 formic acid ethyl ester 
• 474706-74-6 6-bromo-3-iodoimidazo[1,2-a]pyridine 
• 541-41-3 chloroformic acid ethyl ester 
• 1004550-24-6 ethyl 2-chloro-3-oxopropanoate potassium salt 

Downstream Products

• 1276110-06-5 ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]-pyridine-3-carboxylate 
• 1426133-22-3 methyl 3-(3-(3-(6-(3-cyanopropyl)imidazo[1,2-a]pyridine-3-carboxamido)-4-methylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426133-27-8 methyl 3-(3-(3-(6-(2-cyanoethyl)imidazo[1,2-a]pyridine-3-carboxamido)-4-methylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426133-28-9 methyl 3-(3-(4-methyl-3-(6-(3-oxobutyl)imidazo[1,2-a]pyridine-3-carboxamido)phenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426133-30-3 methyl 3-(3-(3-(6-(3-hydroxy-3-methylbutyl)imidazo[1,2-a]pyridine-3-carboxamido)-4-methylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426448-44-3 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(3-oxobutyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426448-45-4 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(3-hydroxy-3-methylbutyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426448-54-5 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[2-(4-methylpiperazin-1-yl)ethyl]imidazo[1,2-a]pyridine-3-carboxamide 
• 1432912-80-5 6-bromo-N-(2,4-dimethoxybenzyl)imidazo[1,2-a]pyridine-3-carboxamide 

Relevant articles and documents

Discovery of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors

Inhibition of cdc2-like kinase1 (CLK1) could efficiently induce autophagy and it has been thought as a potential target for treatment of autophagy-related diseases. Herein we report the discovery of a series of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors. Among them, compound 9e is the most potent one, which exhibits an IC50 value of 4 nM against CLK1 kinase. In vitro, this compound reduces the phosphorylation level of the typical downstream substrates of CLK1 and affects their subcellular redistribution. Further study indicates that 9e is efficient to induce autophagy. Overall, this study provides a promising lead compound for drug discovery targeting CLK1 kinase.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2- a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.

Convenient two-step one-pot synthesis of 3-substituted imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines

Abstract: A convenient and novel two-step one-pot method for the synthesis of 3-substituted imidazo[1,2-a]pyridines and 3-substituted imidazo[1,2-b]pyridazines was developed through the reaction of heterocyclic amines and N,?N-dimethylformamide dimethyl a